Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy
BACKGROUNDIn the single-arm CHRYSALIS trial, advanced non-small cell lung cancer patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon 20ins) showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with EGFR Exon 20ins. This study compar...
Gespeichert in:
| Veröffentlicht in: | Acta oncologica 2023-12, Vol.62 (12), p.1689-1697 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1697 |
|---|---|
| container_issue | 12 |
| container_start_page | 1689 |
| container_title | Acta oncologica |
| container_volume | 62 |
| creator | Kim, Tae Min Girard, Nicolas Low, Grace Kah Mun Zhuo, Jianmin Yu, Dae Young Yang, Yishen Murota, Maiko Lim, Cindy Thiow Koon Kleinman, Nora J. Cho, Byoung Chul |
| description | BACKGROUNDIn the single-arm CHRYSALIS trial, advanced non-small cell lung cancer patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon 20ins) showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with EGFR Exon 20ins. This study compared the effectiveness of amivantamab to real-world systemic anti-cancer therapies in Japan.PATIENTS AND METHODSExternal control patients were selected by applying CHRYSALIS eligibility to Japanese patients from LC-SCRUM-Asia. External control patients were included for every qualifying line of therapy after platinum-based chemotherapy. Propensity score weighting was applied to external control patients to adjust for differences in baseline characteristics. Outcomes were compared between external control patients, and all and Asian-only CHRYSALIS patients using weighted Cox proportional hazards regression models for progression-free survival (PFS), time to next therapy (TTNT), and overall survival (OS), and generalized estimating equations with repeated measurements for overall response rate (ORR).RESULTSOne hundred fifteen CHRYSALIS and 94 external control patients were identified. Compared to external control patients, amivantamab-treated patients had significantly longer OS (median OS 19.88 vs 14.09 months, HR [95% CI] 0.59 [0.40-0.88]), PFS (median PFS 6.74 vs 4.73 months, HR 0.59 [0.45-0.78]), TTNT (median TTNT 12.16 vs 5.09 months, HR 0.39 [0.29-0.53]), and significantly higher ORR (41.7% vs 14.1%). Analyses of amivantamab-treated Asian patients (n = 61) showed similar clinical benefits.CONCLUSIONIn the absence of clinical evidence from randomized clinical trials, this study reflects the benefit of amivantamab after platinum-based chemotherapy for advanced non-small cell lung cancer patients harboring EGFR Exon 20ins, compared to current real-world therapies. |
| doi_str_mv | 10.1080/0284186X.2023.2254479 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2887474958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2887474958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-2380546739f452a61094ed4657f6e83ac81580d12f49de586a0c33000b492cf93</originalsourceid><addsrcrecordid>eNo1kdFKwzAUhoMoOKePIOTSm84kTdr0coxtCgNBFHZXztLUVZq0JqlzL-RzmrJ5c3J-8p3_kPwI3VMyo0SSR8IkpzLbzhhh6YwxwXleXKAJzQRNGMu2l2gyMskIXaMb7z8JiWguJuh3bppvsAEM7LDqTA9OV_jQhD12Gtrk0Lm2wmGvHfSN9rixuIfQaBv8iYIqjqs4YzubeANti5WOpR3sB1bjlcPL9eoVL386ixmJDl670ERhhgBj4zHUIWJ9G6UdTLIDHw3VXpvutPl4i65qaL2-O59T9L5avi2eks3L-nkx3ySKSRoSlkoieJanRc0Fg4ySguuKZyKvMy1TUJIKSSrKal5UWsgMiErT-Bk7XjBVF-kUPZx8e9d9DdqH0jR-fA9Y3Q2-ZFLmPOeFkBEVJ1S5znun67J3jQF3LCkpx1zK_1zKMZfynEv6B9msgy0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2887474958</pqid></control><display><type>article</type><title>Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Taylor & Francis:Master (3349 titles)</source><source>Alma/SFX Local Collection</source><creator>Kim, Tae Min ; Girard, Nicolas ; Low, Grace Kah Mun ; Zhuo, Jianmin ; Yu, Dae Young ; Yang, Yishen ; Murota, Maiko ; Lim, Cindy Thiow Koon ; Kleinman, Nora J. ; Cho, Byoung Chul</creator><creatorcontrib>Kim, Tae Min ; Girard, Nicolas ; Low, Grace Kah Mun ; Zhuo, Jianmin ; Yu, Dae Young ; Yang, Yishen ; Murota, Maiko ; Lim, Cindy Thiow Koon ; Kleinman, Nora J. ; Cho, Byoung Chul</creatorcontrib><description>BACKGROUNDIn the single-arm CHRYSALIS trial, advanced non-small cell lung cancer patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon 20ins) showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with EGFR Exon 20ins. This study compared the effectiveness of amivantamab to real-world systemic anti-cancer therapies in Japan.PATIENTS AND METHODSExternal control patients were selected by applying CHRYSALIS eligibility to Japanese patients from LC-SCRUM-Asia. External control patients were included for every qualifying line of therapy after platinum-based chemotherapy. Propensity score weighting was applied to external control patients to adjust for differences in baseline characteristics. Outcomes were compared between external control patients, and all and Asian-only CHRYSALIS patients using weighted Cox proportional hazards regression models for progression-free survival (PFS), time to next therapy (TTNT), and overall survival (OS), and generalized estimating equations with repeated measurements for overall response rate (ORR).RESULTSOne hundred fifteen CHRYSALIS and 94 external control patients were identified. Compared to external control patients, amivantamab-treated patients had significantly longer OS (median OS 19.88 vs 14.09 months, HR [95% CI] 0.59 [0.40-0.88]), PFS (median PFS 6.74 vs 4.73 months, HR 0.59 [0.45-0.78]), TTNT (median TTNT 12.16 vs 5.09 months, HR 0.39 [0.29-0.53]), and significantly higher ORR (41.7% vs 14.1%). Analyses of amivantamab-treated Asian patients (n = 61) showed similar clinical benefits.CONCLUSIONIn the absence of clinical evidence from randomized clinical trials, this study reflects the benefit of amivantamab after platinum-based chemotherapy for advanced non-small cell lung cancer patients harboring EGFR Exon 20ins, compared to current real-world therapies.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.1080/0284186X.2023.2254479</identifier><language>eng</language><ispartof>Acta oncologica, 2023-12, Vol.62 (12), p.1689-1697</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c281t-2380546739f452a61094ed4657f6e83ac81580d12f49de586a0c33000b492cf93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27928,27929</link.rule.ids></links><search><creatorcontrib>Kim, Tae Min</creatorcontrib><creatorcontrib>Girard, Nicolas</creatorcontrib><creatorcontrib>Low, Grace Kah Mun</creatorcontrib><creatorcontrib>Zhuo, Jianmin</creatorcontrib><creatorcontrib>Yu, Dae Young</creatorcontrib><creatorcontrib>Yang, Yishen</creatorcontrib><creatorcontrib>Murota, Maiko</creatorcontrib><creatorcontrib>Lim, Cindy Thiow Koon</creatorcontrib><creatorcontrib>Kleinman, Nora J.</creatorcontrib><creatorcontrib>Cho, Byoung Chul</creatorcontrib><title>Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy</title><title>Acta oncologica</title><description>BACKGROUNDIn the single-arm CHRYSALIS trial, advanced non-small cell lung cancer patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon 20ins) showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with EGFR Exon 20ins. This study compared the effectiveness of amivantamab to real-world systemic anti-cancer therapies in Japan.PATIENTS AND METHODSExternal control patients were selected by applying CHRYSALIS eligibility to Japanese patients from LC-SCRUM-Asia. External control patients were included for every qualifying line of therapy after platinum-based chemotherapy. Propensity score weighting was applied to external control patients to adjust for differences in baseline characteristics. Outcomes were compared between external control patients, and all and Asian-only CHRYSALIS patients using weighted Cox proportional hazards regression models for progression-free survival (PFS), time to next therapy (TTNT), and overall survival (OS), and generalized estimating equations with repeated measurements for overall response rate (ORR).RESULTSOne hundred fifteen CHRYSALIS and 94 external control patients were identified. Compared to external control patients, amivantamab-treated patients had significantly longer OS (median OS 19.88 vs 14.09 months, HR [95% CI] 0.59 [0.40-0.88]), PFS (median PFS 6.74 vs 4.73 months, HR 0.59 [0.45-0.78]), TTNT (median TTNT 12.16 vs 5.09 months, HR 0.39 [0.29-0.53]), and significantly higher ORR (41.7% vs 14.1%). Analyses of amivantamab-treated Asian patients (n = 61) showed similar clinical benefits.CONCLUSIONIn the absence of clinical evidence from randomized clinical trials, this study reflects the benefit of amivantamab after platinum-based chemotherapy for advanced non-small cell lung cancer patients harboring EGFR Exon 20ins, compared to current real-world therapies.</description><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo1kdFKwzAUhoMoOKePIOTSm84kTdr0coxtCgNBFHZXztLUVZq0JqlzL-RzmrJ5c3J-8p3_kPwI3VMyo0SSR8IkpzLbzhhh6YwxwXleXKAJzQRNGMu2l2gyMskIXaMb7z8JiWguJuh3bppvsAEM7LDqTA9OV_jQhD12Gtrk0Lm2wmGvHfSN9rixuIfQaBv8iYIqjqs4YzubeANti5WOpR3sB1bjlcPL9eoVL386ixmJDl670ERhhgBj4zHUIWJ9G6UdTLIDHw3VXpvutPl4i65qaL2-O59T9L5avi2eks3L-nkx3ySKSRoSlkoieJanRc0Fg4ySguuKZyKvMy1TUJIKSSrKal5UWsgMiErT-Bk7XjBVF-kUPZx8e9d9DdqH0jR-fA9Y3Q2-ZFLmPOeFkBEVJ1S5znun67J3jQF3LCkpx1zK_1zKMZfynEv6B9msgy0</recordid><startdate>20231202</startdate><enddate>20231202</enddate><creator>Kim, Tae Min</creator><creator>Girard, Nicolas</creator><creator>Low, Grace Kah Mun</creator><creator>Zhuo, Jianmin</creator><creator>Yu, Dae Young</creator><creator>Yang, Yishen</creator><creator>Murota, Maiko</creator><creator>Lim, Cindy Thiow Koon</creator><creator>Kleinman, Nora J.</creator><creator>Cho, Byoung Chul</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20231202</creationdate><title>Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy</title><author>Kim, Tae Min ; Girard, Nicolas ; Low, Grace Kah Mun ; Zhuo, Jianmin ; Yu, Dae Young ; Yang, Yishen ; Murota, Maiko ; Lim, Cindy Thiow Koon ; Kleinman, Nora J. ; Cho, Byoung Chul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-2380546739f452a61094ed4657f6e83ac81580d12f49de586a0c33000b492cf93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Tae Min</creatorcontrib><creatorcontrib>Girard, Nicolas</creatorcontrib><creatorcontrib>Low, Grace Kah Mun</creatorcontrib><creatorcontrib>Zhuo, Jianmin</creatorcontrib><creatorcontrib>Yu, Dae Young</creatorcontrib><creatorcontrib>Yang, Yishen</creatorcontrib><creatorcontrib>Murota, Maiko</creatorcontrib><creatorcontrib>Lim, Cindy Thiow Koon</creatorcontrib><creatorcontrib>Kleinman, Nora J.</creatorcontrib><creatorcontrib>Cho, Byoung Chul</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Tae Min</au><au>Girard, Nicolas</au><au>Low, Grace Kah Mun</au><au>Zhuo, Jianmin</au><au>Yu, Dae Young</au><au>Yang, Yishen</au><au>Murota, Maiko</au><au>Lim, Cindy Thiow Koon</au><au>Kleinman, Nora J.</au><au>Cho, Byoung Chul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy</atitle><jtitle>Acta oncologica</jtitle><date>2023-12-02</date><risdate>2023</risdate><volume>62</volume><issue>12</issue><spage>1689</spage><epage>1697</epage><pages>1689-1697</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><abstract>BACKGROUNDIn the single-arm CHRYSALIS trial, advanced non-small cell lung cancer patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon 20ins) showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with EGFR Exon 20ins. This study compared the effectiveness of amivantamab to real-world systemic anti-cancer therapies in Japan.PATIENTS AND METHODSExternal control patients were selected by applying CHRYSALIS eligibility to Japanese patients from LC-SCRUM-Asia. External control patients were included for every qualifying line of therapy after platinum-based chemotherapy. Propensity score weighting was applied to external control patients to adjust for differences in baseline characteristics. Outcomes were compared between external control patients, and all and Asian-only CHRYSALIS patients using weighted Cox proportional hazards regression models for progression-free survival (PFS), time to next therapy (TTNT), and overall survival (OS), and generalized estimating equations with repeated measurements for overall response rate (ORR).RESULTSOne hundred fifteen CHRYSALIS and 94 external control patients were identified. Compared to external control patients, amivantamab-treated patients had significantly longer OS (median OS 19.88 vs 14.09 months, HR [95% CI] 0.59 [0.40-0.88]), PFS (median PFS 6.74 vs 4.73 months, HR 0.59 [0.45-0.78]), TTNT (median TTNT 12.16 vs 5.09 months, HR 0.39 [0.29-0.53]), and significantly higher ORR (41.7% vs 14.1%). Analyses of amivantamab-treated Asian patients (n = 61) showed similar clinical benefits.CONCLUSIONIn the absence of clinical evidence from randomized clinical trials, this study reflects the benefit of amivantamab after platinum-based chemotherapy for advanced non-small cell lung cancer patients harboring EGFR Exon 20ins, compared to current real-world therapies.</abstract><doi>10.1080/0284186X.2023.2254479</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta oncologica, 2023-12, Vol.62 (12), p.1689-1697 |
| issn | 0284-186X 1651-226X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2887474958 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Taylor & Francis:Master (3349 titles); Alma/SFX Local Collection |
| title | Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T22%3A00%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amivantamab%20compared%20with%20real-world%20therapies%20in%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%20EGFR%20Exon%2020%20insertion%20mutations%20after%20platinum-based%20chemotherapy&rft.jtitle=Acta%20oncologica&rft.au=Kim,%20Tae%20Min&rft.date=2023-12-02&rft.volume=62&rft.issue=12&rft.spage=1689&rft.epage=1697&rft.pages=1689-1697&rft.issn=0284-186X&rft.eissn=1651-226X&rft_id=info:doi/10.1080/0284186X.2023.2254479&rft_dat=%3Cproquest_cross%3E2887474958%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2887474958&rft_id=info:pmid/&rfr_iscdi=true |